Literature DB >> 6702753

Cell surface blood group antigens in prostatic carcinoma.

P D Walker, S Karnik, J B deKernion, J C Pramberg.   

Abstract

Surface blood group antigens are present to some degree in most epithelia. These antigens frequently are lost during neoplastic transformation. The authors looked for the presence or absence of surface blood group antigens in 52 cases of prostatic carcinoma of various histologic grades using the specific red blood cell adherence test. The normal prostatic tissue showed a 2+ reaction in patients with type A or B blood and 0-1+ in type O. The hyperplastic areas were 4+ for red blood cell adherence in patients with type A or B blood and 0-4+ in type O. In contrast, all malignant foci were negative for blood group antigens, no matter what the histologic grade or blood type.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6702753     DOI: 10.1093/ajcp/81.4.503

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  Deletion of antigens of the Lewis a/b blood group family in human prostatic carcinoma.

Authors:  W W Young; S E Mills; M C Lippert; P Ahmed; S K Lau
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

2.  Biological tissue markers in benign and malignant disease of the human prostate.

Authors:  P Chastonay; J Hurlimann; D Gardiol
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

3.  The Relationship between ABO Blood Groups and Acne Vulgaris.

Authors:  Erdinç Terzi; Belma Türsen; Pınar Dursun; Teoman Erdem; Ümit Türsen
Journal:  Saudi J Med Med Sci       Date:  2015-12-02

Review 4.  Glycosylation Changes in Prostate Cancer Progression.

Authors:  William Butler; Jiaoti Huang
Journal:  Front Oncol       Date:  2021-12-24       Impact factor: 6.244

Review 5.  The role of glycans in the development and progression of prostate cancer.

Authors:  Jennifer Munkley; Ian G Mills; David J Elliott
Journal:  Nat Rev Urol       Date:  2016-04-19       Impact factor: 14.432

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.